Promising Canadian-developed Ebola vaccine licensed to drug giant Merck

November 24, 2014 1:29 PM

3 0

The small U.S. company that holds the rights to a Canadian-developed Ebola vaccine has agreed to licence it to vaccine giant Merck, which should speed the development of the product that scientists hope will eventually end the outbreak in West Africa.

Merck announced the deal in a news release before markets opened on Monday, saying the firm had reached a deal with NewLink Genetics for “an exclusive worldwide license agreement to research, develop, manufacture, and distribute” the vaccine.

Also read: Sanofi Partnership Passes First Test With Delivery of Antibiotic Compounds

Read more

To category page

Loading...